COVID-19 Antigen Assay

SARS-CoV-2 Antigen ELISA Kit:

The Solsten SARS-CoV-2 Antigen ELISA Kit is a CE-marked in vitro diagnostic product with unique characteristics:

  • It quantifies the nucleocapsid protein antigen of SARS-CoV-2 in blood samples
  • It demonstrates COVID-19 at the same early stage of infection as PCR-analysis
  • It has an accuracy, specificity and sensitivity at the level of PCR-analysis of upper respiratory swabs

See recent peer-reviewed publication in J. Clinical Microbiology:

These characteristics makes the Solsten SARS-CoV-2 Antigen ELISA Kit particularly suitable for:

Screening for SARS-CoV-2 hospital (nosocomial) infections, since:

  • The blood samples (serum or plasma) have already been collected for other analytical purposes
  • Additional sampling by staff is avoided.
  • One technician can analyse several hundred blood samples by ELISA in one batch-run.
  • The analysis time of the ELISA is 2 hours per batch-run, and it is easy to automate.
  • The price of ELISA-screening is at least 4x lower per patient than testing by PCR.

The SARS-CoV-2 N Antigen Quantitative Rapid Test

The SARS-CoV-2 N Antigen Rapid Test is done in 15 minutes, and the concentration of SARS-CoV-2 nucleocapsid (N) antigen is measured as a fluorescence signal by the BOH-180 Instrument.”

  • Easy-to-use Quantitative Rapid Test for the N antigen in blood.
  • Use one drop of blood (20 µl of fingerprick full blood or 10 µl of serum/plasma from a venous blood sample).
  • The result is achieved in 15 minutes including quantitative reading in 20 seconds by the Fluorescence Immunoassay Analyzer Instrument”
  • Clinically documented, CE-IVD marked quantitative rapid test (see correlation to ELISA results below).
  • Reading of test result requires the Fluorescence Immunoassay Analyzer Instrument.

Read more about Fluorescence Immunoassay Analyzer Instrument

A high correlation was observed, when the nucleocapsid antigen concentration of 131 plasma samples from 58 COVID-19 infected (PCR-positive) and 72 healthy (PCR-negative) individuals were determined by the SARS-CoV-2 N Antigen Quantitative Rapid Test and checked by the SARS-CoV-2 N Antigen ELISA.